76 related articles for article (PubMed ID: 32387182)
1. Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation.
Tao G; Chityala PK; Li L; Lin Z; Ghose R
Chem Biol Interact; 2022 Jun; 360():109946. PubMed ID: 35430260
[TBL] [Abstract][Full Text] [Related]
2. Role of MRPs transporters in pharmacokinetics and intestinal toxicity of irinotecan.
Du T; Luo T; Wang J; Sun R; Cai H
Food Chem Toxicol; 2023 Dec; 182():114171. PubMed ID: 37956707
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and emerging strategies for irinotecan-induced diarrhea.
Xu S; Lan H; Huang C; Ge X; Zhu J
Eur J Pharmacol; 2024 Jul; 974():176614. PubMed ID: 38677535
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy.
Bhatt AP; Pellock SJ; Biernat KA; Walton WG; Wallace BD; Creekmore BC; Letertre MM; Swann JR; Wilson ID; Roques JR; Darr DB; Bailey ST; Montgomery SA; Roach JM; Azcarate-Peril MA; Sartor RB; Gharaibeh RZ; Bultman SJ; Redinbo MR
Proc Natl Acad Sci U S A; 2020 Mar; 117(13):7374-7381. PubMed ID: 32170007
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis.
He Y; Wu L; Qi X; Wang X; He B; Zhang W; Zhao W; Deng M; Xiong X; Wang Y; Liang S
Integr Cancer Ther; 2024; 23():15347354241242110. PubMed ID: 38567795
[TBL] [Abstract][Full Text] [Related]
6. Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicity.
Lin HY; Chen CY; Lin TC; Yeh LF; Hsieh WC; Gao S; Burnouf PA; Chen BM; Hsieh TJ; Dashnyam P; Kuo YH; Tu Z; Roffler SR; Lin CH
Commun Biol; 2021 Mar; 4(1):280. PubMed ID: 33664385
[TBL] [Abstract][Full Text] [Related]
7. An Organ-on-Chip Platform for Simulating Drug Metabolism Along the Gut-Liver Axis.
Lucchetti M; Aina KO; Grandmougin L; Jäger C; Pérez Escriva P; Letellier E; Mosig AS; Wilmes P
Adv Healthc Mater; 2024 Mar; ():e2303943. PubMed ID: 38452399
[TBL] [Abstract][Full Text] [Related]
8. Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.
Eades W; Liu W; Shen Y; Shi Z; Yan B
Curr Drug Metab; 2022 Dec; ():. PubMed ID: 36515038
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of irinotecan in patients with chronic kidney disease: Two cases and literature review.
Chui CY; Moes DJAR; Koolen SLW; Swen JJ; Gelderblom H
Br J Clin Pharmacol; 2023 Sep; 89(9):2920-2925. PubMed ID: 37337890
[TBL] [Abstract][Full Text] [Related]
10. Optimized rat models better mimic patients with irinotecan-induced severe diarrhea.
Zheng Z; Du T; Gao S; Yin T; Li L; Zhu L; Singh R; Sun R; Hu M
Toxicol Mech Methods; 2024 Jun; 34(5):572-583. PubMed ID: 38390772
[TBL] [Abstract][Full Text] [Related]
11. The role of gut microbial β-glucuronidase in drug disposition and development.
Gao S; Sun R; Singh R; Yu So S; Chan CTY; Savidge T; Hu M
Drug Discov Today; 2022 Oct; 27(10):103316. PubMed ID: 35820618
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy induced gastrointestinal toxicities.
Akbarali HI; Muchhala KH; Jessup DK; Cheatham S
Adv Cancer Res; 2022; 155():131-166. PubMed ID: 35779873
[TBL] [Abstract][Full Text] [Related]
13. α-Glucosidase and Bacterial β-Glucuronidase Inhibitors from the Stems of
Rao G; Yu H; Zhang M; Cheng Y; Ran K; Wang J; Wei B; Li M; Shan W; Zhan Z; Ying Y
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337127
[TBL] [Abstract][Full Text] [Related]
14. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity.
Tao G; Huang J; Moorthy B; Wang C; Hu M; Gao S; Ghose R
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1109-1124. PubMed ID: 32841068
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt.
Sun R; Zhu L; Li L; Song W; Gong X; Qi X; Wang Y; Ghose R; Gao S; Hu M; Liu Z
Toxicol Appl Pharmacol; 2020 Jul; 398():115032. PubMed ID: 32387182
[TBL] [Abstract][Full Text] [Related]
16. Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea.
Sun R; Basu S; Zeng M; Sunsong R; Li L; Ghose R; Wang W; Liu Z; Hu M; Gao S
Curr Cancer Drug Targets; 2019; 19(7):551-560. PubMed ID: 31509102
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea.
Tao G; Dagher F; Li L; Singh R; Hu M; Ghose R
Food Chem Toxicol; 2022 Aug; 166():113246. PubMed ID: 35728726
[TBL] [Abstract][Full Text] [Related]
18. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
